Sjogren’s syndrome

1. High-Yield Summary

• Systemic Autoimmune Exocrinopathy: Characterized by chronic lymphocytic infiltration of exocrine glands, predominantly the lacrimal and salivary glands, resulting in classic keratoconjunctivitis sicca (dry eyes) and xerostomia (dry mouth). Primary Sjögren syndrome (pSS) occurs in isolation, whereas secondary Sjögren syndrome (sSS) develops in the setting of established connective tissue disease, most commonly rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE).
• Musculoskeletal Manifestations: Polyarthralgias and intermittent non-erosive polyarthritis affect over 50% to 70% of patients, typically following a symmetrical distribution involving the small joints of the hands, wrists, and knees without marginal erosions or joint destruction.
• Diagnostic Gold Standard & Criteria: Definitive classification relies on the 2016 ACR-EULAR criteria (score ≥ 4), integrating focal lymphocytic sialadenitis on minor labial salivary gland biopsy (focus score ≥ 1/4 mm²), anti-SSA/Ro autoantibody seropositivity, ocular staining score ≥ 5, Schirmer test ≤ 5 mm/5 min, and unstimulated whole saliva flow rate ≤ 0.1 mL/min.
• Critical Orthopaedic & Perioperative Hazards: Severe risk of intraoperative corneal ulceration and abrasion under general anesthesia due to absent basal tear production; mandatory eye protection with lubricating ointment and occlusive taping is required. Patients on immunosuppressive DMARDs require structured perioperative management according to ACR/AAHKS guidelines to mitigate prosthetic joint infection (PJI) risk while preventing inflammatory flares.
• Malignancy Surveillance: Carries a 15- to 20-fold increased risk of non-Hodgkin B-cell lymphoma (predominantly MALT lymphoma of salivary glands). Persistent, firm, unilateral salivary gland enlargement, cryoglobulinemia, or hypocomplementemia (low C3/C4) demands immediate biopsy and oncologic staging.

2. Anatomy

Understanding the pertinent surgical and regional anatomy is critical for clinicians performing diagnostic tissue biopsies, evaluating glandular masses, and managing musculoskeletal manifestations.

Salivary and Lacrimal Gland Architecture

• Minor Labial Salivary Glands: Clustered within the submucosal stroma of the inner lower lip, deep to the non-keratinized stratified squamous epithelium and superficial to the orbicularis oris muscle fibers. Each gland measures 1 to 3 mm and drains via short independent excretory ducts into the oral vestibule.
• Major Salivary Glands: The parotid, submandibular, and sublingual glands. The parotid gland occupies the retromandibular fossa, enveloped by the superficial investing layer of deep cervical fascia. The facial nerve (CN VII) traverses the parotid substance, bifurcating at the pes anserinus into temporofacial and cervicofacial trunks, separating the gland into superficial and deep lobes.
• Lacrimal Apparatus: Located in the superolateral orbit within the lacrimal fossa of the frontal bone. Serous acini produce the aqueous layer of the trilaminar tear film, which lubricates the corneal and conjunctival epithelium.

Surgical Exposure & Neurovascular Danger Zones for Labial Biopsy

• Internervous & Incision Plane: Minor salivary gland biopsy is performed through a transverse mucosal incision on the inner aspect of the lower lip, positioned midway between the vermilion border and the labial sulcus. The incision must be placed strictly lateral to the midline.
• Neurovascular Structures at Risk: The mental nerve (sensory branch of the mandibular division of the trigeminal nerve, V3) exits the mental foramen beneath the premolars and arborizes within the lower lip. Dissection carried too deeply into the orbicularis oris muscle or excessively lateral into the labial commissure risks sensory terminal branch laceration, causing permanent lip numbness or paresthesia. Dissection must remain strictly superficial to the muscle fascia.
• Vascular Supply: The inferior labial artery, a major branch of the facial artery, courses deep to the orbicularis oris near the vermilion border. Superficial mucosal incisions avoid arterial bleeding; minor capillary oozing is controlled with gentle pressure or bipolar cautery.

Articular and Musculoskeletal Anatomy

Sjögren syndrome arthropathy involves synovial membranes without promoting aggressive osteoclastogenesis or pannus formation seen in rheumatoid arthritis. Synovial hypertrophy remains mild and non-destructive. Tendon sheaths of the hand and wrist (extensor retinaculum compartments and flexor tenosynovium) can exhibit low-grade lymphocytic tenosynovitis, occasionally causing carpal tunnel syndrome through median nerve compression beneath the transverse carpal ligament.

3. Pathogenesis

The pathogenesis of Sjögren syndrome represents a multistep autoimmune cascade centered on “autoimmune epithelitis,” where mucosal epithelial cells play an active immunoregulatory role in triggering and sustaining chronic glandular destruction.

Genetic Susceptibility and Environmental Triggers

• Genetic Predisposition: Strongly associated with human leukocyte antigen (HLA) class II alleles, primarily HLA-DRB1*0301 (DR3), HLA-DQA1*0501, and HLA-DQB1*0201 in Caucasian cohorts. Non-HLA loci implicated include STAT4, IRF5, and TNFAIP3, genes involved in type I interferon signaling and NF-κB activation.
• Viral Triggers: Environmental insults, including Epstein-Barr virus (EBV), cytomegalovirus (CMV), hepatitis C virus (HCV), and coxsackievirus, trigger innate immune responses through Toll-like receptors (TLR-3, TLR-7, TLR-9) on ductal epithelial and plasmacytoid dendritic cells.

Autoimmune Epithelitis & Lymphocytic Infiltration

• Epithelial Activation: Glandular epithelial cells aberrantly express MHC class II molecules, CD80/CD86 co-stimulatory receptors, and adhesion molecules (ICAM-1). They secrete chemokines (CXCL12, CXCL13, CCL21) that promote the selective homing of lymphocytes to periductal areas.
• T-Cell Orchestration: In early stages, CD4+ T helper cells predominate within glandular foci, producing type 1 interferons, interferon-gamma (IFN-γ), and interleukin-17 (IL-17). Follicular helper T cells (Tfh) facilitate germinal center formation within target tissues.
• B-Cell Hyperactivation & BAFF Axis: Epithelial and dendritic cells hypersecrete B-cell activating factor (BAFF/BLyS). Excessive BAFF promotes autoreactive B-cell survival, polyclonal hypergammaglobulinemia, autoantibody generation, and ectopic germinal center development. Chronic monoclonal expansion predisposes to malignant transformation into B-cell lymphomas.
• Neurosecretory Dysfunction: Autoantibodies directed against muscarinic acetylcholine type 3 receptors (M3R) competitively block parasympathetic signaling to acinar cells, suppressing salivary and tear secretion prior to complete anatomical glandular atrophy.

4. Natural History

The natural history of primary Sjögren syndrome is typically chronic, progressive, and indolent, though a subset of patients experiences severe systemic extraglandular involvement or hematologic malignancy.

Epidemiology

• Prevalence & Incidence: The pooled global prevalence of primary Sjögren syndrome is estimated at 60.82 per 100,000 inhabitants. It represents the second most common systemic autoimmune rheumatic disease after rheumatoid arthritis.
• Demographics: Striking female predilection with a female-to-male ratio of 9:1. Peak incidence occurs between the fourth and sixth decades of life (ages 40 to 60), although juvenile and geriatric presentations are well documented.

Disease Trajectory & Prognosis

• Exocrine Sicca Progression: Progressive dry mouth leads to rampant dental caries, enamel erosion, oral candidiasis, and dysphagia. Chronic keratoconjunctivitis sicca leads to corneal erosions, infectious keratitis, and rarely corneal perforation.
• Extraglandular Articular Involvement: Recurrent non-erosive polyarthralgias affect 50% to 70% of patients, and transient non-deforming synovitis occurs intermittently without pannus formation.
• Extraglandular Neurologic Manifestations: Peripheral neuropathy affects 16.7% of patients, presenting as sensory axonal polyneuropathy, painful small-fiber neuropathy, autonomic neuropathy, or mononeuritis multiplex.
• Extraglandular Pulmonary & Renal Disease: Interstitial lung disease (nonspecific interstitial pneumonia [NSIP] or lymphocytic interstitial pneumonia [LIP]) develops in 10% to 15% of patients. Distal renal tubular acidosis (type 1 RTA) with hypokalemic periodic paralysis or nephrocalcinosis occurs in 5% to 10%.
• Extraglandular Vascular Manifestations: Cutaneous purpura, Raynaud phenomenon (15% to 30%), and cryoglobulinemic vasculitis affect subsets with active systemic disease.
• Mortality & Malignancy: Overall life expectancy is comparable to the general population in uncomplicated cases. Excess mortality is driven by cardiovascular disease, severe pulmonary fibrosis, cryoglobulinemic vasculitis, and non-Hodgkin lymphoma.

5. Clinical Presentation

History

• Ocular Symptoms: Persistent sensation of foreign body, sand, or gravel in the eyes; burning, photophobia, eye fatigue, and intolerance to contact lenses lasting > 3 months.
• Oral Symptoms: Daily feeling of dry mouth for > 3 months; inability to swallow dry food (such as crackers) without sipping liquids (“cracker sign”); accelerated cervical dental caries; altered taste (dysgeusia); recurrent painful swelling of the parotid or submandibular glands.
• Musculoskeletal Symptoms: Symmetrical joint aching in MCP, PIP, wrist, and knee joints; morning stiffness lasting 15 to 45 minutes (distinctly shorter than rheumatoid arthritis); absence of severe joint contractures or progressive subluxations.
• Constitutional & Neuropathic Symptoms: Severe debilitating fatigue disproportionate to exertion, diffuse myalgias, and burning paresthesias in a stocking-and-glove distribution indicative of small-fiber sensory neuropathy.

Physical Exam

• Tongue Blade Sign: A dry wooden tongue depressor adheres to the buccal mucosa upon retraction due to complete absence of normal salivary film [Sensitivity 80%, Specificity 75%].
• Salivary Pool Inspection: Complete absence of normal clear pooling of saliva in the sublingual caruncles and floor of the mouth.
• Glandular Palpation: Bilateral or unilateral enlargement of parotid and submandibular glands. Normal glands are soft and non-tender; firm, nodular, or asymmetric enlargement warrants high suspicion for lymphoma.
• Schirmer Test: Sterile standardized filter paper placed in the lower conjunctival sac without topical anesthesia. A normal result is > 10 mm of wetting at 5 minutes; a positive finding is ≤ 5 mm of wetting at 5 minutes [Sensitivity 75%–85%, Specificity 70%–80%].
• Ocular Surface Staining: Slit-lamp biomicroscopy with fluorescein and lissamine green dyes. An Ocular Staining Score (OSS) ≥ 5 or van Bijsterveld score ≥ 4 reflects punctate epithelial erosions of the cornea and conjunctiva.
• Musculoskeletal Exam: Palpation of MCP, PIP, wrist, elbow, knee, and ankle joints. Symmetrical tenderness without bony enlargement or fixed deformities. Synovial effusions, when present, are modest. Absence of rheumatoid subcutaneous nodules.

6. Imaging and Diagnostic Studies

Laboratory & Serologic Profiling

• Antinuclear Antibodies (ANA) & Rheumatoid Factor (RF): Positive ANA (speckled pattern) in > 80% of patients; positive RF in 50% to 70% of primary Sjögren syndrome, even in the complete absence of rheumatoid arthritis.
• Anti-SSA (Ro) and Anti-SSB (La): Anti-SSA/Ro is positive in 60% to 80% and represents the core serologic hallmark in classification criteria. Anti-SSB/La is positive in 40% to 60% and is almost exclusively found in conjunction with anti-SSA. Anti-SSA/Ro positivity carries clinical significance for neonatal lupus and congenital heart block in women of childbearing potential.
• Inflammatory Markers & Electrophoresis: Markedly elevated erythrocyte sedimentation rate (ESR > 50 mm/hr) in the setting of normal or marginally elevated C-reactive protein (CRP), a classic serologic dissociation reflecting polyclonal hypergammaglobulinemia rather than acute-phase tissue necrosis. Polyclonal IgG elevation on serum protein electrophoresis (SPEP).
• Hematology & Complement: Mild normocytic anemia (20%), leukopenia/neutropenia (10%–20%). Hypocomplementemia (low C3 and C4) occurs in active systemic disease and signals heightened risk for vasculitis and lymphoma.

Diagnostic Imaging

• Conventional Radiography: Plain radiographs of hands, wrists, and weight-bearing joints reveal preserved joint architecture, normal joint spaces, and absence of marginal bone erosions. Mild periarticular osteopenia may be present. Plain films differentiate Sjögren arthropathy from erosive rheumatoid arthritis or psoriatic arthritis.
• Salivary Gland Ultrasonography (SGUS): High-resolution grayscale and color Doppler evaluation of parotid and submandibular glands. Typical findings include parenchymal inhomogeneity, multiple hypoechoic or anechoic round areas (lymphocytic aggregates and ductal ectasia), hyperechoic bands, and clear gland borders. SGUS exhibits 75% to 85% sensitivity and 85% to 90% specificity, functioning as an accessible, non-invasive imaging modality.
• Advanced Cross-Sectional Imaging (CT & MRI): Magnetic resonance imaging reveals heterogeneous T1 and T2 signals (“salt-and-pepper” or “honeycomb” appearance) in advanced glandular atrophy. Chest high-resolution CT (HRCT) is indicated for chronic cough or dyspnea to identify non-specific interstitial pneumonia (NSIP), lymphocytic interstitial pneumonia (LIP), or bronchiolitis.

Histopathology: Minor Labial Salivary Gland Biopsy

Remains the definitive gold standard diagnostic investigation:

• Specimen Requirement: At least 4 to 6 evaluable glandular lobules (representing ≥ 4 mm² of glandular parenchyma) to prevent sampling error.
• Diagnostic Criterion (Focus Score): Focal lymphocytic sialadenitis defined as ≥ 1 focus per 4 mm² of glandular tissue. A focus is defined as an aggregate of ≥ 50 mononuclear inflammatory cells (predominantly CD4+ T lymphocytes with lesser proportions of B cells and plasma cells) surrounding normal-appearing acini. Focus score ≥ 1 establishes histologic diagnosis and contributes 3 points to the ACR-EULAR classification.

7. Classification

Contemporary clinical trials, epidemiological registries, and clinical practices utilize the 2016 American College of Rheumatology / European League Against Rheumatism (ACR-EULAR) classification criteria for primary Sjögren syndrome.

2016 ACR-EULAR Classification Criteria

Applicable to any patient presenting with at least one symptom of ocular or oral dryness (based on validated questionnaire) or systemic suspicion from the European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index (ESSDAI). Exclusion criteria include past head and neck radiation therapy, active hepatitis C infection (confirmed by PCR), acquired immunodeficiency syndrome (AIDS), sarcoidosis, amyloidosis, graft-versus-host disease, and IgG4-related disease.

Classification Threshold: A sum score of ≥ 4 points classifies an individual as having primary Sjögren syndrome (96% sensitivity, 95% specificity).

Primary vs. Secondary Sjögren Syndrome

8. Treatment

Medical / Nonoperative Management

• Ocular Sicca Therapy: Preservative-free artificial tears (4–6 times daily); lubricating ophthalmic ointments at bedtime; topical ophthalmic cyclosporine 0.05% or lifitegrast 5% for ocular surface inflammation. Temporary or permanent punctal occlusion (plugs or electrocautery) preserves natural tears.
• Oral Sicca Therapy: Frequent water sips; sugar-free xylitol gum or lozenges; saliva substitutes; meticulous oral hygiene and chlorhexidine rinses. Systemic secretagogues (pilocarpine 5 mg PO TID-QID or cevimeline 30 mg PO TID) stimulate functional muscarinic M3 receptors in residual acini.
• First-Line Analgesics for Musculoskeletal Symptoms: Paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs) for intermittent mild arthralgias. Short-course low-dose oral corticosteroids (prednisone 5–10 mg/day) for acute articular flares.
• Conventional Synthetic DMARDs: Hydroxychloroquine (HCQ, 5 mg/kg actual body weight/day, maximum 400 mg/day) is the cornerstone disease-modifying therapy for inflammatory polyarthralgias, recurrent synovitis, constitutional fatigue, and cutaneous manifestations. Annual ophthalmologic screening for retinal toxicity is mandatory. Methotrexate (10–25 mg/week orally or subcutaneously with folic acid) or leflunomide (20 mg/day) is reserved for persistent synovitis refractory to HCQ.
• Biologic Therapy for Severe Extraglandular Disease: Rituximab (1,000 mg IV on days 0 and 14) is indicated for cryoglobulinemic vasculitis, severe peripheral neuropathy, cutaneous vasculitis, and refractory parotid gland enlargement. Moderate to high-dose systemic glucocorticoids (prednisone 0.5–1.0 mg/kg/day or IV methylprednisolone pulses) are utilized for acute organ-threatening flares.
• Immunosuppressive Agents: Cyclophosphamide or mycophenolate mofetil is reserved for organ-threatening disease, such as rapidly progressive glomerulonephritis or progressive interstitial lung disease.

Operative & Perioperative Management in Orthopaedic Surgery

Surgical intervention in primary Sjögren syndrome is primarily directed at elective reconstructive orthopaedics (such as total hip and knee arthroplasty for concurrent osteoarthritis) and minor diagnostic procedures (labial biopsy).

• Mandatory Intraoperative Corneal Protection: The absence of normal basal tear secretion puts Sjögren patients under general anesthesia at extreme risk for corneal abrasions, exposure keratopathy, epithelial sloughing, and subsequent microbial keratitis. Anesthesia and surgical teams must apply preservative-free ophthalmic lubricant ointment immediately upon induction and seal both eyelids securely with occlusive hypoallergenic tape.
• Airway & Oropharyngeal Considerations: Severe xerostomia creates fragile mucosal surfaces vulnerable to traumatic endotracheal intubation. Gentle laryngoscopy, moist throat packs, and continuous humidification of inspired anesthetic gases are required.
• Perioperative Hydroxychloroquine: Continue without interruption throughout the perioperative window. HCQ does not increase prosthetic joint infection risk, and holding it risks postoperative autoimmune flares.
• Perioperative Methotrexate & Leflunomide: Continue methotrexate throughout elective arthroplasty in patients with stable disease, as established by randomized prospective registry data showing no increased PJI risk.
• Perioperative Biologic Agents (Rituximab): Schedule elective surgery at the end of the dosing cycle (e.g., month 6 or 7 following a 6-month rituximab infusion), when B-cell counts begin recovery, and resume 2 to 4 weeks postoperatively following complete surgical wound healing and suture removal.
• Perioperative Corticosteroids: Patients on chronic prednisone > 5 mg/day require careful perioperative maintenance; physiologic replacement (20–25 mg hydrocortisone equivalent) is maintained to prevent adrenal crisis without routine massive stress doses.
• Minor Labial Salivary Gland Biopsy Technique: Under local mucosal infiltration (1% lidocaine with 1:100,000 epinephrine), a 1 to 1.5 cm horizontal incision is made through the labial mucosa lateral to the midline. Blunt dissection isolates 4 to 6 distinct glandular lobules from surrounding connective tissue, taking care not to violate the underlying orbicularis oris muscle. Mucosa is closed with interrupted 5-0 rapidly absorbable sutures (polyglactin 910 or chromic gut).

Indications & Contraindications

• Indications for Labial Salivary Gland Biopsy: High clinical suspicion of Sjögren syndrome with negative or equivocal anti-SSA serology, or suspected systemic autoimmune disease where tissue confirmation of focal lymphocytic sialadenitis is mandatory.
• Indications for Major Salivary Gland Biopsy: Rapid, asymmetric, firm, or nodular enlargement of the parotid gland, facial nerve palsy, or constitutional B-symptoms (fever, night sweats, weight loss) to exclude non-Hodgkin lymphoma.
• Indications for Total Joint Arthroplasty: End-stage degenerative osteoarthritis or secondary avascular necrosis failing ≥ 6 months of nonoperative management.
• Contraindications: Elective orthopaedic surgery is contraindicated during acute systemic vasculitic flares, uncontrolled cryoglobulinemia, untreated severe cytopenias, or active ocular infection.

9. Outcome

• Articular Function and Joint Preservation: Unlike rheumatoid arthritis, primary Sjögren syndrome causes non-erosive arthropathy. Long-term structural joint damage is rare, and radiographic progression to secondary osteoarthritis occurs at rates comparable to age-matched controls. Conservative therapy with hydroxychloroquine yields symptomatic control of polyarthralgias in > 70% of patients.
• Total Joint Arthroplasty Outcomes: Primary hip and knee arthroplasty in Sjögren syndrome patients achieve excellent long-term implant survivorship (> 92% at 10 years). Validated patient-reported outcome measures (PROMs), including the Hip Disability and Osteoarthritis Outcome Score (HOOS) and Knee Injury and Osteoarthritis Outcome Score (KOOS), demonstrate substantial pain relief and functional restoration.
• Patient-Reported Quality of Life: Measured via the EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI, assessing dryness, pain, and fatigue) and Short Form-36 (SF-36). Chronic fatigue and dry eye/mouth discomfort represent the primary long-term determinants of impaired quality of life.

10. Complications

11. Pearls and Pitfalls

• Pearl (Mandatory Eye Care): Every orthopaedic patient with known Sjögren syndrome or persistent dry eyes must have prophylactic ocular lubricant ointment and occlusive tape applied before general anesthesia induction to prevent devastating postoperative corneal abrasions and exposure keratitis.
• Pearl (Biopsy Precision): When harvesting minor labial salivary glands, dissect strictly lateral to the midline and remain entirely superficial to the orbicularis oris muscle. This safeguards the terminal sensory branches of the mental nerve and prevents permanent numbness of the lower lip.
• Pearl (ESR-CRP Dissociation): A markedly elevated ESR with a completely normal CRP is a classical hallmark of Sjögren syndrome, reflecting hypergammaglobulinemia rather than acute bacterial infection. If the CRP is also elevated, thoroughly investigate for concurrent infection or systemic vasculitis.
• Pitfall (Stopping Hydroxychloroquine): Abruptly discontinuing hydroxychloroquine prior to elective arthroplasty increases the risk of severe postoperative musculoskeletal flare without conferring any reduction in prosthetic joint infection risk. HCQ should be continued uninterrupted.
• Pitfall (Overlooking Lymphoma Warning Signs): Never dismiss a persistently swollen, firm, or asymmetric parotid gland in a Sjögren patient as simple autoimmune sialadenitis. New-onset firm enlargement, hypocomplementemia (low C4), or cryoglobulinemia warrants immediate tissue biopsy to rule out B-cell non-Hodgkin lymphoma.
• Pitfall (Misdiagnosing Joint Destruction): Symmetrical polyarthralgias in Sjögren syndrome are non-erosive. Identifying marginal erosions or rapid articular collapse on plain radiographs indicates an overlap syndrome with rheumatoid arthritis or a secondary Sjögren syndrome rather than primary pSS.

12. Controversy

• B-Cell Targeted Biologics in Primary Sicca Symptoms: Although early open-label trials suggested marked benefits with rituximab, two major randomized controlled trials (TEARS and TRACTISS) failed to achieve their primary clinical endpoints of reducing fatigue and oral dryness. Controversy persists regarding the routine use of rituximab, with current European guidelines restricting its use strictly to severe systemic extraglandular disease (vasculitis, severe neuropathy, cryoglobulinemia, refractory parotitis) rather than uncomplicated glandular sicca syndrome.
• Incorporation of Salivary Gland Ultrasound (SGUS) into Formal Classification: While SGUS demonstrates high diagnostic accuracy and excellent inter-observer reliability in skilled centers, it was not formally incorporated into the weighted 2016 ACR-EULAR classification criteria due to a lack of global standardization across ultrasonography machines and sonographers. Recent international multicenter initiatives (OMERACT) have standardized scoring systems, and whether SGUS will replace invasive labial biopsy or ocular staining in future classification criteria revisions remains actively debated.
• Novel Biologic Targets (BAFF-R & CD40 Blockade): Emerging therapies targeting the B-cell survival pathway, such as ianalumab (VAY736, a dual-action BAFF receptor monoclonal antibody) and CD40-CD40L pathway inhibitors, have demonstrated significant reductions in disease activity scores (ESSDAI) in phase 2b trials. Determining the optimal patient subset for early aggressive biologic therapy versus conventional synthetic DMARDs represents a primary active research focus.

13. Evidence-Based Synthesis

Modern clinical decision-making is grounded in high-quality randomized controlled trials and prospective registry analyses, corroborated by seminal biomechanical and anatomical descriptions.

14. References

• Liampas A, Parperis K, Erotocritou MF et al. Primary Sjögren syndrome-related peripheral neuropathy: A systematic review and meta-analysis. Eur J Neurol. 2023. doi:10.1111/ene.15555 [Level I: Systematic Review / Meta-Analysis]
• Bowman SJ, Fox R, Dörner T et al. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren’s syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet. 2022. doi:10.1016/S0140-6736(21)02251-0 [Level I: Randomized Controlled Trial]
• Qin B, Wang J, Yang Z et al. Epidemiology of primary Sjögren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 2015. doi:10.1136/annrheumdis-2014-205375 [Level I: Systematic Review / Meta-Analysis]
• Shiboski CH, Shiboski SC, Seror R et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome. Ann Rheum Dis. 2017. doi:10.1136/annrheumdis-2016-210571 [Level II: Consensus & Multicenter Validation Study]
• Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002. doi:10.1136/ard.61.6.554 [Level II: Multicenter International Validation Study]

15. Master Class Pro-Tip

In patients with confirmed or suspected Sjögren syndrome undergoing major orthopaedic surgery under general anesthesia, never rely on passive eyelid closure. Loss of the basal tear film leads to rapid corneal desiccation within 15 minutes of anesthetic gas exposure. The surgical team must mandate the application of preservative-free ocular lubricant ointment followed immediately by occlusive hypoallergenic eyelid taping prior to intubation. When diagnostic tissue confirmation is required, perform the minor labial salivary gland biopsy strictly lateral to the midline and remain entirely superficial to the orbicularis oris muscle to safeguard the sensory branches of the mental nerve. Continue hydroxychloroquine uninterrupted throughout the perioperative window, as empirical discontinuation precipitates severe postoperative inflammatory flares without offering any protection against surgical site infection.

Master Class Surgical Pearl: Perioperative Safeguards and Gland Biopsy Precision in Sjögren Syndrome